Morphine

Generic Name: Morphine

Brand Names: Arymo, Avinza, Doloral, Duramorph, Embeda, Infumorph, Kadian, M-ediat, M-eslon, MSIR, Mitigo, Ms Contin, Statex

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₉NO_₃

CAS Number: 57-27-2

Unique Ingredient Identifier: 76I7G6D29C

Background: Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as codeine, fentanyl, methadone, hydrocodone, hydromorphone, meperidine, and oxycodone.

Morphine was granted FDA approval in 1941.

Indication: Morphine is used for the management of chronic, moderate to severe pain.

Opiods, including morphine, are effective for the short term management of pain. Patients taking opioids long term may need to be monitored for the development of physical dependence, addiction disorder, and drug abuse.

Associated Conditions: Chronic Pain, Severe Pain

Associated Therapies: -

Clinical Trials

Epidural Morphine for Analgesia After Traumatic Vaginal Delivery

Phase 4

Withdrawn

Conditions: Traumatic Vaginal Delivery

Interventions: Drug: Placebo
Drug: Morphine

First Posted Date: 2012-09-21

Last Posted Date: 2017-09-26

Lead Sponsor: Lawson Health Research Institute

Registration Number: NCT01689597

Investigating the Safety of Post-surgical Analgesics in Children With Obstructive Sleep Apnea

Phase 3

Conditions: Pediatric Obstructive Sleep Apnea Syndrome

Interventions: Drug: Morphine
Drug: Ibuprofen

First Posted Date: 2012-09-07

Last Posted Date: 2013-05-27

Lead Sponsor: Hamilton Health Sciences Corporation

Target Recruit Count: 120

Registration Number: NCT01680939

Locations: 🇨🇦
McMaster University Medical Centre, Hamilton, Ontario, Canada

Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance

Phase 4

Active, not recruiting

Conditions: Chronic Pain

Interventions: Drug: Placebo
Drug: Morphine
Drug: Guanfacine 2mg
Drug: Guanfacine 1mg

First Posted Date: 2012-09-07

Last Posted Date: 2023-03-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 200

Registration Number: NCT01681264

Locations: 🇺🇸
Center for Translational Pain Research, Boston, Massachusetts, United States

Immediate-Release Oxycodone Capsules Study in Cancer Pain

Phase 3

Completed

Conditions: Cancer

Interventions: Drug: Oxycodone
Drug: Morphine

First Posted Date: 2012-08-30

Last Posted Date: 2018-05-21

Lead Sponsor: Mundipharma (China) Pharmaceutical Co. Ltd

Target Recruit Count: 242

Registration Number: NCT01675622

Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Morphine Sulfate

First Posted Date: 2012-08-15

Last Posted Date: 2012-08-15

Lead Sponsor: Ranbaxy Inc.

Target Recruit Count: 26

Registration Number: NCT01665222

Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Morphine Sulfate

First Posted Date: 2012-08-15

Last Posted Date: 2012-08-15

Lead Sponsor: Ranbaxy Inc.

Target Recruit Count: 24

Registration Number: NCT01665209

5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence

Not Applicable

Completed

Conditions: Opioid Withdrawal
Physical Dependence

Interventions: Drug: Ondansetron
Drug: Placebo
Drug: Morphine
Drug: Naloxone 0.4 mg/70 kg
Drug: Naloxone 0.8 mg/70 kg

First Posted Date: 2012-03-09

Last Posted Date: 2019-01-07

Lead Sponsor: Stanford University

Target Recruit Count: 133

Registration Number: NCT01549652

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Buprenorphine in Acute Renal Colic Pain Management

Phase 4

Completed

Conditions: Acute Pain Management
Renal Colic

Interventions: Drug: Buprenorphine
Drug: Morphine

First Posted Date: 2012-03-07

Last Posted Date: 2012-12-10

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 80

Registration Number: NCT01546701

Locations: 🇮🇷
TUMS, Tehran, Iran, Islamic Republic of

Low Dose Ketamine (LDK) Versus Morphine for Acute Pain Control in the Emergency Department

Phase 4

Completed

Conditions: Abdomen, Acute
Other Acute Pain
Back Pain
Musculoskeletal Pain
Flank Pain

Interventions: Drug: Ketamine
Drug: Morphine

First Posted Date: 2012-02-24

Last Posted Date: 2021-02-04

Lead Sponsor: Brooke Army Medical Center

Target Recruit Count: 45

Registration Number: NCT01538745

Locations: 🇺🇸
Brooke Army Medical Center, San Antonio, Texas, United States

The Effect of Morphine on Prasugrel Absorption in STEMI Patients

Phase 4

Completed

Conditions: Cardiovascular Disease

Interventions: Drug: saline
Drug: morphine

First Posted Date: 2012-02-22

Last Posted Date: 2022-06-14

Lead Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust

Target Recruit Count: 12

Registration Number: NCT01536964

Locations: 🇬🇧
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy